Randomized controlled trial of early, small-volume formula supplementation among newborns: A study protocol

Amy Sarah Ginsburg1, Augusto Braima de Sa2, Victoria Nankabirwa3,4

  • 1University of Washington, Seattle, WA, United States of America.

Plos One
|February 4, 2022
PubMed

Insights

Supplementing exclusive breastfeeding (EBF) with small-volume formula may improve infant weight-for-age z-scores in early infancy. This randomized controlled trial evaluated formula efficacy in low birth weight infants, finding potential benefits for growth outcomes.

Area of Science:

  • Global Health
  • Pediatrics
  • Nutritional Science

Background:

  • Childhood undernutrition is a significant global health issue, leading to increased morbidity, mortality, and long-term developmental impairments.
  • The early postnatal period is critical for establishing healthy infant growth and development.
  • While exclusive breastfeeding (EBF) is recommended, some infants may require supplementation to meet nutritional needs.

Purpose of the Study:

  • To evaluate the efficacy of daily, small-volume formula supplementation compared to EBF alone in improving growth outcomes for low birth weight (LBW) infants.
  • To test the hypothesis that formula supplementation increases weight-for-age z-score (WAZ) at 30 days of infant age.

Main Methods:

  • A randomized controlled trial involving 324 mother-infant pairs in Guinea-Bissau and Uganda.
  • Infants received either EBF with daily formula supplementation (up to 59 ml) or EBF alone for 30 days.
  • Follow-up for 6 months assessed growth, intestinal microbiota, breastfeeding duration, dietary intake, and adverse events.

Main Results:

  • The study aimed to detect a difference of 0.20 in WAZ at day 30 between intervention groups.
  • Sample size calculations provided ≥80% power, accounting for an estimated 20% loss to follow-up.

Conclusions:

  • Early formula supplementation alongside breastfeeding may be a viable strategy to mitigate underweight, wasting, and stunting in early infancy.
  • Further analysis of the collected data will elucidate the impact of supplementation on growth and other key infant health indicators.

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
21
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
5
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
8